Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Fundacio Institut de Recerca Biomedica (Irb Barcelona) |
| Country | Spain |
| Start Date | Mar 01, 2025 |
| End Date | Feb 28, 2029 |
| Duration | 1,460 days |
| Number of Grantees | 22 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101169223 |
Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending to equip budding researchers with the necessary skills to emerge as leaders in this field.
A robust mentoring and training strategy, coupled with cutting-edge methodologies and a diverse range of complementary soft skills, are crucial to this endeavour.
These skills are imparted through local and network-wide events, fostering seamless research progression, and nurturing successful career trajectories.
Scientifically, Adaptmet addresses an unmet medical need by harnessing basic science to revolutionize drug development and, ultimately, enhance patient care.
Specifically, scientific work packages (WPs) have been designed to approach metastasis from various functional perspectives. In order to metastasize, cancer cells must adeptly coordinate diverse cellular functions (Cell Fate - WP1).
Additionally, understanding the intricate interactions between metastatic cells, the host immune system, and tissue stroma is pivotal (Environment – WP2).
Crucial aspects such as the kinetics of metastasis and the mechanisms governing latency, particularly, remain inadequately understood (Latency – WP3).
Clarifying this complexity, unravelling mechanisms underlying therapy failure, and identifying expansion pathways are central to defining novel therapeutic targets (Expansion – WP4).
In essence, Adaptmet stands at the intersection of a rapidly evolving multidisciplinary domain, amalgamating distinct fields that often face challenges in mutual communication.
The success of Adaptmet hinges upon robust partnerships, open exchange of ideas, state-of-the-art methodologies and equipment, and the exploitation of synergistic opportunities among network members.
This collaboration spans diverse perspectives, bridging gaps between different disciplines, thereby breaking down barriers and fostering interdisciplinary cohesion.
Academisch Ziekenhuis Leiden; Helsingin Yliopisto; Universite de Lausanne; Lunds Universitet; Universitat Basel; Universitat Wien; Cancer State Therapeutics; Gr Espanol de Estudio Y Tratamientode Intensific. Y Otras Estrateg.Experiment. En Tumores Solidos - Grupo Solti; Universite Libre de Bruxelles; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Fundacio Institut de Recerca Biomedica (Irb Barcelona); Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis; Universitat de Barcelona; Saso Kocevar; Scienseed Sl; Danmarks Tekniske Universitet; Fundacio Institut Hospital Del Mar D Investigacions Mediques; Institute of Cancer Research: the Royal Cancer Hospital Lbg; Boehringer Ingelheim Rcv Gmbh & Co Kg; Zs Associates As; Fundacio Institut de Recerca Contra la Leucemia Josep Carreras; Forschungsinstitut Fur Molekulare Pathologie Gesellschaft Mbh
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant